Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts

Liver Transplantation

Volumn 12, Issue 10, 2006, Pages 1496-1503

  Khapra, Asma Poonawala ^a,c   Agarwal, Kaushik ^a   Fiel, Maria Isabel ^a   Kontorinis, Nickolas ^a   Hossain, Sabera ^b   Emre, Sukru ^b   Schiano, Thomas D ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERFERON; MYCOPHENOLIC ACID; OKT 3; PEGINTERFERON; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DONOR; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES; DATABASES AS TOPIC; DISEASE PROGRESSION; FEMALE; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33750129323     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20849     Document Type: Article

References (24)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-65S.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
3. United Network for Organ Sharing. 2004 Annual Report.
4. Montalti R, Nardo B, Bertelli R, Beltempo P, Puviani L, Vivarelli M, Cavallari A. Donor pool expansion in liver transplantation. Transplant Proc 2004;36:520-522.
5. Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl 2004; 10: 1263-1268.
6. Yersiz H, Renz JF, Farmer DG, Hisatake GM, McDiarmid SV, Busuttil RW. One hundred in situ split-liver transplantations: a single-center experience. Annals of Surgery 2003;238:496-505 [Discussion 506-507].
7. Testa G, Goldstein RM, Netto G, Abbasoglu O, Brooks BK, Levy MF, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 1998;65:925-929.
8. Velidedeoglu E, Desai NM, Campos L, Olthoff KM, Shaked A, Nunes F, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002;73:582-587.
9. Marroquin CE, Marino G, Kuo PC, Plotkin JS, Rustgi VK, Lu AD, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 200 1;7:762-768.
10. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts inlivertransplantation. Liver Transpl 2003; 9: S48-51.
11. Sheiner PA, Mor E, Schwartz ME, Miller CM. Use of hepatitis C-positive donors in liver transplantation. Transplant Proc 1993;25:3071.
12. Torres M, Weppler D, Reddy KR, Tzakis A. Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology 1999; 117:1253.
13. Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003:9:1053-1061.
14. Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant 2003;3:1167-1172.
15. Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117:149-153.
16. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
17. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
18. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
19. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124:97-104.
20. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
21. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-393 [Discussion 393-394].
22. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
23. Vargas V, Comas P, Castells L, Quer J, Esteban JI, Allende E, et al. Incidence and outcome of hepatitis C virus infection after liver transplantation. Transpl Int 1994;7(Suppl 1):S216-S220.
24. Rifai K, Sebagh M, Karam V, Saliba F, Azoulay D, Adam R, et al Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004;41:446-453.